Abstract: The present disclosure provides, in part, a solvent composition including an an acetic acid alkyl (C1-C4) ester (e.g., methyl acetate (MA), ethyl acetate (EA), or tert-butyl acetate (TBAc)) and a carbonate ester (e.g., dimethyl carbonate, or propylene carbonate).
Abstract: Disclosed herein is a dispersion comprising a liquid or semi-solid continuous phase, a dispersed solid phase comprising a plurality of organic, inorganic or inorganic-organic particles, and an alkyl ketal ester having the structure wherein a is 0 or an integer of 1 to 12, specifically 1 to 6, more specifically 1 to 4; b is 0 or 1; R2 is a divalent C1-8 group optionally substituted with up to 5 hydroxyl groups; and R1 is C1-6 alkyl, and wherein at least a portion of the alkyl ketal ester is present in the continuous phase, on a surface of at least some of the dispersed particles, or a combination thereof.
Type:
Grant
Filed:
March 31, 2014
Date of Patent:
February 24, 2015
Inventors:
Lee Richard Rieth, Dorie J. Yontz, Nicholas Morante
Abstract: The present invention is drawn to a process for improving the efficiency of sunscreens using a series of polyesters based upon sorbeth ethoxylates esterified with fatty acids, then crosslinked with dimer acid. These polyesters exhibit a synergistic interaction with sunscreen actives improving the efficiency providing a “shield” for the body from the harmful effects of the sun. These sorbitol alkoxylates are then reacted with dimer acid, resulting in a series of novel polyesters. The linking of the two spider esters together with dimer provide an amphilic macromolecule possessing both hydrophilic and hydrophobic portions covalently bonded to the same molecule, this provides both a boost in sun protection factor (SPF) and the ability for the sunscreen actives to be applied to wet skin.
Abstract: A pest controlling composition comprising tolclofos-methyl and a neonicotinoid compound represented by the formula (1) as active ingredients.
Abstract: Disclosed are compositions for stabilizing a source of active halogen in aqueous solution. The compositions comprise (i) at least one substituted N-hydrogen compound, such as 5,5-dimethylhydantoin, and (ii) at least one additional nitrogen compound selected from ammonia, ammonium salts, and nitrogen compounds containing no carbon-hydrogen bonds, the molar ratio of (i) and (ii) being in the range of 50:1 to 0.02:1. Active halogen-containing aqueous solutions stabilized by the above compositions are particularly useful for controlling microbial and planktonic growth in aqueous systems such as process liquids in the pulping or papermaking industry. The compositions are also useful in reducing the corrosivity of halogen-containing solutions.
Type:
Grant
Filed:
July 26, 2010
Date of Patent:
January 13, 2015
Assignee:
Lonza Inc.
Inventors:
Kevin E. Janak, Sarah Elizabeth Kopecky, Michael Leonid Ludensky, Philip Gerdon Sweeny
Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Type:
Grant
Filed:
July 17, 2012
Date of Patent:
January 13, 2015
Assignee:
Allergan, Inc.
Inventors:
Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
Abstract: An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster.
Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
Type:
Grant
Filed:
January 14, 2013
Date of Patent:
January 6, 2015
Assignee:
Santen Pharmaceutical Co., Ltd.
Inventors:
Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
Abstract: The invention provides intradialytic parenteral nutrition (IDPN) compositions with low carbohydrate for the treatment of malnutrition in dialysis subjects. In some embodiments, the IDPN compositions are advantageous for the treatment of malnutrition in subjects who are diabetic or suffer from other glucose management related pathologies or subjects who benefit from strict fluid management.
Abstract: The present invention is directed to a co-attrited stabilizer composition comprising: (i) microcrystalline cellulose and (ii) carboxymethyl cellulose, wherein the carboxymethyl cellulose has a degree of substitution of from 0.95-1.5 and a viscosity of less than 100 cps. The composition is useful as a stabilizer, particularly, in food and pharmaceutical applications.
Type:
Grant
Filed:
November 30, 2012
Date of Patent:
January 6, 2015
Assignee:
FMC Corporation
Inventors:
Zheng Tan, Aaron Chip Venables, Michael Sestrick, Nadia Yaranossian, Jeremy Ondov
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Abstract: The present invention relates to a composition including at least one C7 sugar, or derivative from esterification of said sugar, and a pharmaceutically acceptable carrier for treating alopecia. The present invention also relates to a method for cosmetically treating hair and nails, said method being intended to stimulate the growth thereof and/or slow the loss thereof. According to said method, a cosmetic composition including at least one C7 sugar, or derivative from esterification of said sugar, is administered. The present invention finally relates to a method for cosmetic care of hair and/or eyelashes and/or nails.
Abstract: The invention relates to a cosmetic preparation containing (a) esters of fatty acids having 6 to 12 carbon atoms with pentaerythritol and (b) silicones.
Type:
Grant
Filed:
March 5, 2011
Date of Patent:
November 25, 2014
Assignee:
Cognis IP Management GmbH
Inventors:
Markus Dierker, Hans-Martin Haake, Daniela Prinz, Junko Kano, Kakushi Doki, Tae-Seong Kim, Koichi Masaki, Sybille Cornelsen
Abstract: There is provided a plant disease controlling composition comprising at least one compound (A) selected from the group consisting of metconazole, bromuconazole and epoxyconazole, as well as a compound represented by the formula (I): as active ingredients. Also provided is a method for controlling a plant disease, which comprises applying at least one compound (A) selected from the group consisting of metconazole, bromuconazole and epoxyconazole, as well as the compound represented by the formula (I) to a plant, a seed of a plant or a cropland.
Abstract: The present invention relates to a method of producing a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerized into beads.
Abstract: Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1?) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1? prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1?.
Abstract: Provided herein are novel compounds based on xanthene, for example biarsenical compounds, which are useful as molecular probes. The compounds contain at least one isotope atom, such as a radioisotope atom. Methods for visualizing tetracysteine-tagged analyte molecules such as proteins using said compounds, methods for synthesizing said compounds, and methods for treating cancer or other hyperproliferative disorders using said compounds are also provided.
Type:
Grant
Filed:
November 15, 2011
Date of Patent:
October 7, 2014
Assignee:
Biopercept AB
Inventors:
Hans Eric Peter Strom, Samuel Par Simon Svensson
Abstract: The present invention relates to compositions and methods for treating and preventing skeletal muscle deficiencies. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P188) and methods of using the same for treating and preventing skeletal muscle deficiencies and injuries (e.g., dystrophin-deficient skeletal muscle; skeletal muscle having a contraction force deficit; skeletal muscle having a Ca2+ imbalance; skeletal muscle having microtears).
Type:
Grant
Filed:
December 17, 2008
Date of Patent:
October 7, 2014
Assignees:
The Regents of the University of Michigan, Phrixus Pharmaceuticals, Inc.
Inventors:
Rainer Ng, Joseph M. Metzger, Lorraine Reeve, Bruce Markham
Abstract: The present invention provides compositions comprising allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages. In some embodiments a positive charge and enhancers are used in the compositions to allow for increased penetration of the active ingredient through skin and skin appendages. In some embodiments the positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The present invention also provides methods for making compositions comprising an allylamine drug compound, and methods of using such compositions for the treatment of fungal infections of the skin and skin appendages.
Abstract: The present invention relates to the use of selective insecticidal compositions, characterized by an effective amount of an active compound combination comprising (a) (1) at least one haloalkylnicotinic acid derivative of the formula (I) in which AA and R1A are as defined in the description, or (2) at least one phthalic acid diamide of the formula (II) in which XB, R1B, R2B, R3B, L1B, L2B and L3B are as defined in the description, or (3) at least one anthranilamide of the formula (III) in which A1C, A2C, XC, R1C, R2C, R3C, R4C, R5C, R7C, R8C and R9C are as defined in the description, and (b) at least one crop plant compatibility-improving compound from the group of compounds given in the description, in particular cloquintocet-mexyl, isoxadifen-ethyl and mefenpyr-diethyl for controlling insects and/or arachnids, and a method for controlling insects and/or arachnids using the compositions.
Type:
Grant
Filed:
December 3, 2013
Date of Patent:
September 23, 2014
Assignee:
Bayer CropScience AG
Inventors:
Reiner Fischer, Rüdiger Fischer, Christian Funke, Achim Hense, Wolfram Andersch, Heike Hungenberg, Wolfgang Thielert, Udo Reckmann, Lothar Willms, Christian Arnold